Treatment of pre- and postmenopausal Women with HR+/HER2-metastatic Breast Cancer Ribociclib receives high AGO Recommendation Level

被引：0
|
作者：
Rudesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [21] Identifying drivers of first-line HR+/HER2-metastatic breast cancer treatment choices
    Brufsky, Adam
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Kurosky, Samantha K.
    Arruda, Lillian Shahied
    Heck, Wendy
    Cha-Silva, Ashley S.
    FUTURE ONCOLOGY, 2024, 20 (29) : 2165 - 2177
  • [22] Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2-metastatic breast cancer
    Carter, Gebra Cuyun
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Smith, Emily Nash
    Mathur, Raina
    Cohen, Aaron B.
    Baxi, Shrujal
    Rybowski, Sarah
    Chong, Amy Lee
    Seidman, Andrew D.
    CANCER RESEARCH, 2020, 80 (04)
  • [23] VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA
    Chin, A.
    Ip, Q.
    Wu, X.
    Lyle, D.
    VALUE IN HEALTH, 2024, 27 (06) : S163 - S163
  • [24] Identifying Drivers of First-Line HR+/HER2-Metastatic Breast Cancer Treatment Choices
    Brufsky, Adam M.
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Cha, Ashley S.
    Arruda, Lillian Shahied
    Heck, Wendy
    Kurosky, Samantha K.
    CANCER RESEARCH, 2023, 83 (05)
  • [25] Patient and treatment characteristics in HR+/HER2-metastatic breast cancer in a real-life setting
    Karadurmus, Nuri
    Sendur, Mehmet Ali Nahit
    Cil, Timucin
    Oksuzoglu, Omur Berna Cakmak
    Arslan, Cagatay
    Harputluoglu, Hakan
    Goksu, Sema Sezgin
    Ozturk, Banu
    MevludeInanc
    Cubukcu, Erdem
    Demirci, Umut
    Erdem, Dilek
    Cihan, Sener
    Tural, Deniz
    Dumludag, Aysegul
    Yilmaz, Funda
    Avsar, Esin
    Sonusen, Sermin Dinc
    Ozturk, Ozge Fulya
    Aver, Birkan
    Kaplan, Muhammet Ali
    CANCER RESEARCH, 2023, 83 (05)
  • [26] The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2-metastatic breast cancer
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    Ribnikar, Domen
    Kuhar, Cvetka Grasic
    Cankar, Kaja
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Everolimus-based combination therapies for HR+, HER2-metastatic breast cancer
    O'Shaughnessy, Joyce
    Beck, J. Thaddeus
    Royce, Melanie
    CANCER TREATMENT REVIEWS, 2018, 69 : 204 - 214
  • [28] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2-Metastatic Breast Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (04): : SP315 - SP315
  • [30] Validation of Claims Algorithm to Identify HR+/HER2-Metastatic Breast Cancer Patients
    Chin, Andi
    Wu, Xiyuan
    Ip, Queeny
    Lyle, Derek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 620 - 620
12345